On Tuesday, Abbott Laboratories (NYSE: ABT) was 0.97% up from the session before settling in for the closing price of $124.57. A 52-week range for ABT has been $110.86 – $141.23.
A company in the Healthcare sector has jumped its sales by 29.98% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 10.32%. With a float of $1.73 billion, this company’s outstanding shares have now reached $1.74 billion.
Abbott Laboratories (ABT) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Abbott Laboratories stocks. The insider ownership of Abbott Laboratories is 0.67%, while institutional ownership is 80.59%. The most recent insider transaction that took place on Nov 25 ’25, was worth 203,043. In this transaction Senior Vice President of this company sold 1,586 shares at a rate of $128.02, taking the stock ownership to the 30,384 shares. Before that another transaction happened on Nov 25 ’25, when Company’s Officer proposed sale 1,586 for $128.02, making the entire transaction worth $203,042.
Abbott Laboratories (ABT) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted 1.34 earnings per share (EPS) during the time that was better than consensus figure (set at 1.34) by -0. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.32% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.29% during the next five years compared to 29.98% growth over the previous five years of trading.
Abbott Laboratories (NYSE: ABT) Trading Performance Indicators
You can see what Abbott Laboratories (ABT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.99. Likewise, its price to free cash flow for the trailing twelve months is 31.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 7.97, a number that is poised to hit 1.50 in the next quarter and is forecasted to reach 5.67 in one year’s time.
Technical Analysis of Abbott Laboratories (ABT)
Let’s dig in a bit further. During the last 5-days, its volume was 4.21 million. That was inferior than the volume of 6.54 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 28.92%.
During the past 100 days, Abbott Laboratories’s (ABT) raw stochastic average was set at 30.26%, which indicates a significant decrease from 56.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.07 in the past 14 days, which was lower than the 2.40 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $126.20, while its 200-day Moving Average is $130.07. However, in the short run, Abbott Laboratories’s stock first resistance to watch stands at $126.53. Second resistance stands at $127.29. The third major resistance level sits at $128.37. If the price goes on to break the first support level at $124.69, it is likely to go to the next support level at $123.61. The third support level lies at $122.85 if the price breaches the second support level.
Abbott Laboratories (NYSE: ABT) Key Stats
There are 1,738,872K outstanding shares of the company, which has a market capitalization of 218.72 billion. As of now, sales total 41,950 M while income totals 13,402 M. Its latest quarter income was 11,369 M while its last quarter net income were 1,644 M.
